NEWTOWN, PA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Forian Inc. (Nasdaq:FORA) announces that Max Wygod, Chief Executive Officer and Executive Chairman, and Mike Vesey, Chief Financial Officer, will attend ROTH MKM’s 12th annual Technology Event, which will be held on November 15, 2023, at the Yale Club in New York City.
This event will provide investors the opportunity to meet with executive management from approximately 60 public companies. The 40-minute management-investor meetings and networking cocktail reception will provide institutional investors with meaningful interaction with executive management to gain in-depth insights.
To learn more and submit a registration request, visit www.roth.com/newyork2023.
About ROTH MKM
ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.
For more information, please visit https://www.roth.com/newyork2023.
About FORIAN INC.
Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments. For more information, please visit Forian’s website at www.forian.com.
Media and Investor Contact:
forian.com/investors
This email address is being protected from spambots. You need JavaScript enabled to view it.
267-225-6263
Last Trade: | US$2.05 |
Daily Change: | 0.09 4.59 |
Daily Volume: | 8,472 |
Market Cap: | US$63.590M |
November 13, 2024 August 14, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load